Latest KRAS Stories
RnRMarketResearch.com adds “Vectibix (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
RnRMarketResearch.com adds “Zaltrap (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with Trovagene's Precision Cancer Monitoring Platform BARCELONA,
Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers
- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.
Surveyed Payers Are Most Receptive to Therapies Offering a Median Overall Survival Benefit over Available Therapies, According to a New Report from Decision Resources Group BURLINGTON, Mass.,
Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and
Large International Cohort of 17 GI Cancer Types Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 1, 2014 /PRNewswire/ -- Caris Life Sciences, a leading